NCT05415657View on ClinicalTrials.gov

Denosumab Effect on Bone Quality and Function After Lumbar Fusion Surgery

NACompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

January 12, 2020

Primary Completion Date

January 5, 2023

Study Completion Date

January 10, 2023

Conditions
OsteopeniaSpine FusionDenosumab Allergy
Interventions
DRUG

Denosumab

Denosumab 60 mg per 6 month were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.

DRUG

Placebo

Equal volume of saline (0.9%) as placebo Q6M were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.

Trial Locations (1)

518000

ShenzhenPH, Shenzhen

All Listed Sponsors
lead

Shenzhen People's Hospital

OTHER

NCT05415657 - Denosumab Effect on Bone Quality and Function After Lumbar Fusion Surgery | Biotech Hunter | Biotech Hunter